Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications
International Journal of Molecular Sciences · 12.02.2025 · 26 (4) · 1562
DOI: 10.3390/ijms26041562 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.02.2025. Verfasst von Alexandros Maniatis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, University of Patras, 26504 Patras, Greece. Hauptthemen laut MEDLINE: Vault Ribonucleoprotein Particles, Neoplasms, Drug Resistance, Neoplasm, Drug Resistance, Multiple. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Vault particles (VPs) are highly conserved large ribonucleoprotein complexes found exclusively in eukaryotes. They play critical roles in various cellular processes, but their involvement in cancer progression and multidrug resistance (MDR) is the most extensively studied. VPs are composed of the major vault protein (MVP), vault RNAs (vtRNAs), vault poly (ADP-ribose) polymerase, and telomerase-associated protein-1. These components are involved in the regulation of signaling pathways that affect tumor survival, proliferation, and metastasis. MVP has been associated with aggressive tumor phenotypes, while vtRNAs modulate cell proliferation, apoptosis, and autophagy. VPs also contribute to MDR by sequestering chemotherapeutic agents, altering their accumulation in the nucleus, and regulating lysosomal dynamics. Furthermore, small vault RNA-derived fragments participate in gene silencing and intercellular communication, reinforcing the role of precursors of vtRNAs in cancer development. Beyond their biological roles, VPs present a promising platform for drug delivery, due to their unique ability to encapsulate a wide range of biomolecules and therapeutic agents, followed by controlled release. This review compiles data from PubMed and Scopus, with a literature search conducted up until December 2024, highlighting current knowledge regarding VPs and their crucial involvement in cancer-related mechanisms and their applications in overcoming cancer drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, School of Medicine, University of Patras, 26504 Patras, Greece.
- Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA.
- Department of Dermatology-Venereology, School of Medicine, University of Patras, 26504 Patras, Greece.
ORCID-Profile: Alexandros Maniatis, Athanasios-Nasir Shaukat, Katerina Grafanaki, Vassiliki Stamatopoulou, Constantinos Stathopoulos
Zitieren
APA
Maniatis, A., Rizopoulou, D., Shaukat, A. N., Grafanaki, K., Stamatopoulou, V., & Stathopoulos, C. (2025). Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications. International Journal of Molecular Sciences, 26(4), 1562. https://doi.org/10.3390/ijms26041562
Vancouver
Maniatis A, Rizopoulou D, Shaukat AN, Grafanaki K, Stamatopoulou V, Stathopoulos C. Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications. International Journal of Molecular Sciences. 2025;26(4):1562. doi:10.3390/ijms26041562
BibTeX
@article{Maniatis2025,
author = {Maniatis, Alexandros and Rizopoulou, Dimitra and Shaukat, Athanasios-Nasir and Grafanaki, Katerina and Stamatopoulou, Vassiliki and Stathopoulos, Constantinos},
title = {Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {4},
pages = {1562},
doi = {10.3390/ijms26041562}
}
EUVIMED